Literature DB >> 18721951

Tap water irrigation and additives to optimize success with the Malone antegrade continence enema: the Indiana University algorithm.

Ahmad H Bani-Hani1, Mark P Cain, Shelly King, Richard C Rink.   

Abstract

PURPOSE: We report the long-term effectiveness of standard tap water for Malone antegrade continence enema irrigation as well as our algorithm for managing refractory constipation/fecal incontinence in a large single institution experience.
MATERIALS AND METHODS: We retrospectively reviewed the charts of 256 Malone antegrade continence enema procedures performed for chronic constipation and/or incontinence due to neuropathic bowel. Continence, type of fluid used to irrigate the colon, volume of flushes and the need for additives were recorded and a database was created. All patients were initially treated with tap water irrigation. Those in whom tap water irrigation failed underwent complete bowel cleanout with enemas and GoLYTELY via the Malone antegrade continence enema, followed by a gradual increase in irrigation volume. If this was unsuccessful, additives of mineral oil, MiraLAX or glycerin were added to the irrigant daily.
RESULTS: A total of 236 patients with at least 6 months of followup were included in this study. Mean age at surgery was 10.2 years (range 2 to 36) and mean followup in the entire cohort was 50 months (range 6 to 115). Mean volume of colonic flushes was 642 ml (range 100 to 1,000). Of the patients 196 (83.1%) achieved total fecal continence with tap water flushes alone. Using additives increased the overall continence rate to 93.6% (p <0.0001).
CONCLUSIONS: The Malone antegrade continence enema procedure has proved invaluable for treating children with refractory constipation. When additives are used in conjunction with water flushes, they can significantly improve the overall fecal continence rate in partially continent children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721951     DOI: 10.1016/j.juro.2008.04.074

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Conservative nonsurgical management of spina bifida.

Authors:  Michael C Carr
Journal:  Curr Urol Rep       Date:  2010-03       Impact factor: 3.092

2.  Neurogenic Bowel Dysfunction in Patients with Neurogenic Bladder.

Authors:  Laura Martinez; Leila Neshatian; Rose Khavari
Journal:  Curr Bladder Dysfunct Rep       Date:  2016-10-20

Review 3.  Current management of fecal incontinence: choosing amongst treatment options to optimize outcomes.

Authors:  Julie Ann M Van Koughnett; Steven D Wexner
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

4.  The role of the retrograde colonic enema in children with spina bifida: is it inferior to the antegrade continence enema?

Authors:  Daisuke Matsuno; Yuichiro Yamazaki; Yoshiyuki Shiroyanagi; Nobufumi Ueda; Mari Suzuki; Morihiro Nishi; Ayako Hagiwara; Terumi Ichiroku
Journal:  Pediatr Surg Int       Date:  2010-03-03       Impact factor: 1.827

5.  Long-term follow-up of patients after antegrade continence enema procedure.

Authors:  Anees A Siddiqui; Steven J Fishman; Stuart B Bauer; Samuel Nurko
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-05       Impact factor: 2.839

6.  Experience with glycerin for antegrade continence enema in patients with neurogenic bowel.

Authors:  David I Chu; Zarine R Balsara; Jonathan C Routh; Sherry S Ross; John S Wiener
Journal:  J Urol       Date:  2012-10-08       Impact factor: 7.450

7.  Antegrade continent enema procedures performed prior to starting school may improve functional stooling and quality of life.

Authors:  Jennifer J Freeman; Siddartha Simha; Marcus D Jarboe; Peter F Ehrlich; Daniel H Teitelbaum
Journal:  Pediatr Surg Int       Date:  2014-05-30       Impact factor: 1.827

Review 8.  Bowel management for the treatment of pediatric fecal incontinence.

Authors:  Andrea Bischoff; Marc A Levitt; Alberto Peña
Journal:  Pediatr Surg Int       Date:  2009-10-15       Impact factor: 1.827

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.